RecruitingPhase 4NCT05302999

Feasibility of Early Gabapentin as an Intervention for Neurorecovery


Sponsor

MetroHealth Medical Center

Enrollment

42 participants

Start Date

Mar 14, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the feasibility of early administration of gabapentin as an intervention for neurorecovery. This research project falls under the Intervention Development stage of research as the primary goal is to assess the feasibility of conducting a well-designed intervention efficacy study in the future.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Traumatic SCI;
  • All levels of SCI;
  • All severities of SCI, AIS A-D;
  • Age 18 years and older.
  • Agree to participate and start study drug within 120 hours' post-injury.
  • Adequate cognition and communication to provide informed consent

Exclusion Criteria2

  • Presence of moderate/severe traumatic brain injury (TBI) as defined by Glasgow Coma Score (GCS) < 13 at 120 hours' post-injury.
  • Documented use of gabapentinoids at the time of injury.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGabapentin

Generic gabapentin

DRUGPlacebo

Inert cellulose


Locations(1)

MetroHealth Medical Center

Cleveland, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05302999


Related Trials